Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)

NCT00479388 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1216

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Hypercholesterolemia
Mixed Dyslipidemia

Interventions

DRUG: Comparator: simvastatin
DRUG: niacin (+) laropiprant
DRUG: Comparator: atorvastatin calcium

Sponsor

Merck Sharp & Dohme LLC